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SObjectives: Esophageal endoscopic ultrasound is now regarded as essential in the staging of esophageal
carcinoma. There is an increasing trend toward endoluminal therapies (ie, endoscopic mucosal resection and
radiofrequency ablation) for pre-cancer or early-stage cancers because of concerns of high morbidity associated
with esophagectomy. This study reviews our institutional experience with preoperative endoscopic ultrasound
staging of early esophageal cancers in patients who underwent an esophagectomy to evaluate the accuracy of
staging by endoscopic ultrasound and how this affects treatment recommendations.
Methods: A prospective esophagectomy database of all patients undergoing an esophagectomy for esophageal
cancer at a single high-volume institution was retrospectively reviewed for patients with early-stage esophageal
cancer. This study analyzed patients with clinical Tis to T1 disease, as predicted by preoperative endoscopic
ultrasound, and correlated this with the pathologic stages after esophagectomy. The surgical outcomes were
evaluated to assess the safety of esophagectomy as a treatment modality.
Results: From 2005 to 2011, 107 patients (93 male, 14 female) with a mean age of 66 years (range, 39-91 years)
were staged by preoperative endoscopic ultrasound to have esophageal high-grade dysplasia, carcinoma in situ,
or T1 cancer and underwent an esophagectomy. Tumor depth was correctly staged by endoscopic ultrasound in
only 39% (23/59) of pT1a tumors (invading into the lamina propria or muscularis mucosa) and 51% (18/35) of
pT1b tumors (submucosal). Of the endoscopic ultrasound–staged cT1a-lpN0 lesions, there were positive lymph
nodes in 15% of pathologic specimens (2/13). Patients with pT1a-mm lesions had a 9% rate of pathologic
lymph node involvement (1/11), and those with pT1b tumors had a 17% rate of lymph node spread (6/35).
Esophagectomy was performed in all 107 patients with a 30-day mortality rate of less than 1% (1/107).
Conclusions: The sensitivity and specificity of endoscopic ultrasound for determining true pathologic staging
are poor for early-stage esophageal cancers. Lesions thought to be cT1a-lpN0 by endoscopic ultrasound have at
least pN1 disease in 15% of cases. Endoluminal therapy of these lesions based on endoscopic ultrasound
undertreats a significant number of patients. Esophagectomy is still the standard therapy for early-stage
esophageal cancers in the majority of patients. (J Thorac Cardiovasc Surg 2014;147:765-73)The National Cancer Institute projects that for 2013 in the
United States, there will be 17,990 new patient diagnoses
of esophageal cancer and 15,210 deaths from the disease.1
The high mortality associated with esophageal cancer is
attributed, at least partially, to the early metastasis and
late clinical presentation of the disease. Although in
historical series, patients with esophageal cancer presented
in advanced stages, more recent series show that with
increased surveillance endoscopy, many patients (33%)
are diagnosed with early-stage (T1) lesions.2 The surveil-
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The Journal of Thoracic and Cawith the potential to progress to esophageal adenocarci-
noma (EAC), allows for potential curative intervention for
lesions detected at early stages. The management of BE
traditionally was based on acid suppression therapy and
serial endoscopic surveillance with methodical biopsies.
Esophagectomy has been the standard management of Tis
and invasive EACs. Despite its success in the eradication
of BE and esophageal cancers, esophagectomy is associated
with a high morbidity and mortality.3 Newer endoscopic-
based therapies have been proposed as alternatives to
esophagectomy for the treatment of Tis or early invasive
EAC. These endoscopic treatments involve the resection
or destruction of the concerning esophageal mucosa.
Endomucosal resection (EMR) is an endoscopic-based
method of resecting esophageal mucosa, allowing for
examination of tumor depth (T stage). Radiofrequency
ablation (RFA) and photodynamic therapy (PDT) are
ablative endoscopic-based therapies that destroy the
targeted tissue but do not allow for the pathologic assess-
ment of the tumor.4 Despite the recent successes of EMR,
RFA, and PDT in abolishing esophageal mucosal lesions,rdiovascular Surgery c Volume 147, Number 2 765
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
EAC ¼ esophageal adenocarcinoma
EMR ¼ endomucosal resection
EUS ¼ endoscopic ultrasound
NPV ¼ negative predictive value
PDT ¼ photodynamic therapy
PET ¼ positron emission tomography
PPV ¼ positive predictive value
RFA ¼ radiofrequency ablation
THE ¼ transhiatal esophagectomy
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Sthese therapies do not address the invasion of deeper layers
or evaluate or treat potential nodal spread.
Endoscopic ultrasound (EUS) is a component of
preoperative staging that directs both esophagectomy and
endoscopic-based therapies.5 EUS allows for the evalua-
tion of esophageal tumors and involved lymph nodes. It
is the principal tool for determining the clinical stage of
the esophageal cancer and the subsequent therapy, which
may include endoscopic-based treatment or surgery,
neoadjuvant chemoradiation followed by surgery, or
definitive chemotherapy with or without radiation. The
aims of this study were to correlate the final pathology
report on esophagectomy specimens in patients diagnosed
with cTis and early-stage esophageal cancers (cTis-cT1),
as determined by EUS, and determine the utility of EUS
in planning therapeutic endoluminal treatments for
early-stage esophageal cancers. The study was designed
to simulate the clinician’s decision-making pathway with
currently used EUS-based staging for early-stage
esophageal cancers. The perioperative outcomes after
esophagectomy also were reviewed to characterize the
risks for patients with early-stage esophageal cancer at
the University of Michigan.MATERIALS AND METHODS
Data for 447 patients in a prospectively collected database who had an
esophagectomy for Tis or esophageal cancer at a single, high-volume
institution between July 7, 2005, and July 7, 2011, were retrospectively
reviewed. The patients had early-stage, Tis or T1, esophageal cancer by
clinical staging with biopsies. All patients underwent a preoperative
EUS, and those diagnosed as having T2 or greater disease depth or
biopsy-proven N1 were excluded. Patients with EUS suspected N1 disease
(but not biopsy confirmed) who proceeded directly to esophagectomy were
included. Suspected lymphadenopathy was defined by the following
criteria: hypoechoic pattern, spherical contour, presence of a distinct
border, and short-axis diameter of 6 mm or greater.6 Patients with lesions
that extended to the cardia of the stomach or who received preoperative
chemotherapy or radiotherapy also were excluded. In the remaining
107 patients, preoperative endoscopic examinations, pathology reports,
operative intervention, cancer staging, and perioperative esophagectomy
outcomes were reviewed.
Standard guidelines for esophageal cancer staging based on the
7th edition of the American Joint Committee on Cancer7 were used.766 The Journal of Thoracic and Cardiovascular SurgThis study analyzed the substages of Tis and T1 disease as predicted by
preoperative EUS and the correlation with pathologic T and N stages.
The preoperative EUS and pathologic T staging was defined as follows:
 Tis: tumor confined to the epithelium and not invading the lamina
propria
 T1a-lp: tumor invading into but not through the lamina propria
 T1a-mm: tumor invasion into but not through muscularis mucosa
 T1b: tumor invasion into but not through the submucosa
If a tumor penetrated more than 1 of the classified tumor depths
described, it was classified as the deepest involved depth. All EUS studies
were performed by experienced endosonographers using Olympus 7.5 and
12 MHz probes (Olympus, Center Valley, Pa). No EUS examinations were
performed by thoracic surgeons. Higher frequency probes (20 and 30MHz)
were not routinely used, nor was their use specifically recorded. Regardless
of the probe type used, a review of the endosonography report resulted in
the clinical EUS stage used. Any EUS reading of possible metastatic
disease within a lymph node was recorded as cN1 disease preoperatively.
The cN1 nodes met the following sonographic criteria: size greater than
1 cm, hypoechoic, distinct margins, and round shape.6 In general, cT or
cN denotes clinical stage determined by EUS, and pT or pN denotes
pathologic stage determined by histopathology.
All esophagectomies were performed by a group of 6 university-based
general thoracic surgeons at a single institution. The accuracy of
preoperative EUS staging was determined by comparing the most recent
EUS staging with the surgical specimen final pathologic reports.
Sensitivity, specificity, accuracy, positive predictive value (PPV), and
negative predictive value (NPV) for metastatic lymph node involvement
by EUS were calculated using standard formulas. The Fisher exact test
was used to determine statistical significance between groups.
Perioperative esophagectomy outcomes were analyzed and included
postoperative hospital length of stay, anastomotic leak, atrial fibrillation,
hoarseness, chylothorax, deep venous thrombosis, wound infection, and
perioperativemortality. Perioperativemortality was defined as death within
30 days of operation or in-hospital mortality. This study was approved by
the University of Michigan Institutional Review Board.
RESULTS
From July 2005 to July 2011, 107 patients (93 male,
87%) with a median age of 66 years (range, 39-91 years)
were staged by preoperative EUS to have esophageal
high-grade dysplasia, carcinoma in situ, or T1 esophageal
cancer and underwent an esophagectomy. Table 1
summarizes the demographic and preoperative clinical
information of the patients studied. The median timing
from EUS to esophagectomy was 59 days; 98.1% (105)
were Caucasian, and 90.7% (97) had distal esophageal
tumors. The most common histology was adenocarcinoma
of the esophagus (89, 83.1%), and 62.6% (67) had Barrett’s
metaplasia in the background of Tis or invasive cancer.
Only 8 patients (7.5%) had squamous cell cancer.
Table 2 displays the preoperative clinical EUS TNM
staging (cT and cN) and post-esophagectomy pathologic
TNM staging (pT and pN) for all 107 patients. All patients
were clinically and pathologically M0. All patients had Tis
or invasive cancer on pathology (pTis or pT1). No patients
after esophagectomy had an absence of carcinoma in situ or
invasive disease on final post-esophagectomy pathology.
None of the 107 patients studied had preoperative or
pathologic distant metastatic disease (cM and pM ¼ 0).ery c February 2014
TABLE 1. Patient demographics and clinical characteristics
Study population, n 107
Age, y, median (range) 66 (39-91)
Gender, n (%)
Male 93 (87%)
Female 14 (13%)
Race, Caucasian/non-Caucasian, n (%)
Caucasian 105 (98.1%)
Non-Caucasian 2 (1.9%)
Tumor location, n (%)
Proximal esophagus 1 (0.9%)
Mid esophagus 9 (8.4%)
Distal esophagus-GE junction 97 (90.7%)
Histopathology
Any presence of Barrett’s metaplasia, n (%) 67 (62.6%)
Adenocarcinoma 89 (83.2%)
Squamous 8 (7.5%)
Carcinoma in situ 9 (8.4%)
Adenosquamous 1 (0.9%)
Type of surgical resection, n (%)
THE with CEGA 105 (98.2%)
3-hole esophagectomy 2 (1.8%)
CEGA, Cervical esophagogastric anastomosis; GE, gastroesophageal; THE, trans-
hiatal esophagectomy.
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The average tumor size in the esophagectomy specimens,
for those with visible lesions, was 8.9 mm (median,
8.0 mm). Nine patients had resection for Tis or carcinoma
confined to the epithelium (pTis). The majority of the
tumors, 55% (59), were confined to the mucosa (pT1a-
lp þ pT1a-mm), whereas 32.7% (35) had only submucosal
(pT1b) deepest involvement. All esophagectomy specimens
had pTis or invasive disease. Tumor depth was correctly
staged by EUS in only 39% (23/59) of pT1a tumors, those
tumors invading into the lamina propria or muscularis
mucosa, and 51% (18/35) of tumors with submucosal
involvement (pT1b). EUS understaged tumor depth in
32% (19/59) of pT1a tumors and 49% (17/35) of pT1b tu-
mors. Overstaging of tumor depth by EUS occurred in 29%
(17/59) pT1a tumors and 51% (18/35) of pT1b tumors.
In particular, 3 tumors on EUS invaded into but not
through the muscularis mucosa (T1a-muscularis mucosa);TABLE 2. cTNM versus pTNM for early-stage esophageal cancers
cTNM pT0 pTis pT1a-lp pT1a-mm pT
All cN0 cT0 0 1 12 3
cTis 0 2 2 2
cT1a-lp 0 2 2 1
cT1a-mm N0 0 2 11 3
cT1a-mm N1 0 0 6 0
cT1b (sm) N0 0 1 11 2
cT1b (sm) N1 0 1 4 0
Total 0 9 48 11
T1a-lp, Furthest invasion into lamina propria; T1a-mm, furthest tumor invasion into musc
The Journal of Thoracic and Ca2 of these tumors were staged as pT2 EACs, and 1 of these
tumors was staged as a pT3 squamous cell carcinoma on
histology.
The sensitivity of EUS for detecting cT1a lamina propria
tumor invasion was 4.16% with a specificity of 81.35%.
Overall sensitivity was 72% for EUS-staged tumors with
invasion superficial to the submucosa (<cT1b) and
specificity of 48.7%.
Lymph Node Evaluation
A total of 1083 lymph nodes underwent pathologic
analysis, and 14 lymph nodes in 9 patients contained
metastatic disease. All 9 patients had adenocarcinomas,
were understaged on tumor depth, and thought to have no
lymph node involvement on preoperative EUS (cN0). Of
these 9 patients, 1 had invasive disease on pathology to
the level of the muscularis mucosa (pT1a-mm), 6 to the
level of the submucosa (pT1b), and the remaining 2 patients
had pT2 disease on final pathology (invasion to the
muscularis propria). Thus, 8 of the 9 patients with positive
pathologic lymph nodes had tumor invasion into the
submucosal level or further. Furthermore, 2 of these
9 patients had 3 or more lymph nodes containing metastatic
disease and were subsequently classified as having pN2
disease. One of these 2 patients with pN2 had tumor
invasion into the submucosa (pT1b) and the other to the
muscularis propria (pT2). Figure 1 shows the prevalence
of metastatic lymph nodes (pN) based on the pathologic
tumor penetration depth. It is notable that 48 patients with
pathologic T1a-lp disease had no evidence of lymph node
spread. One of 11 patients with T1-mm disease did have
lymph node involvement. Only 4 patients had pT2 or
pT3 disease.
Of the EUS-staged cN0 lesions, there were patholo-
gically positive lymph nodes in 15% (2/13) of cT1a lamina
propria lesions and 18% (5 of 28) of cT1a muscularis
mucosa lesions. More specifically, 2 EUS-staged cT1a
muscularis mucosal lesions had pN2 disease on final
pathology, and again, both of these lesions were staged
by EUS as cN0. These 2 tumors were EACs. Overall,
EUS understaged 10% (9/90) of patients with lymph nodespTNM
1b (sm) pT2 pT3 T total pN0 pN1 pN2 N total
1 0 0 17 17 0 0 17
0 0 0 6 6 0 0 6
8 0 0 13 11 2 0 13
8 2 1 27 22 3 2 27
0 0 0 6 6 0 0 6
12 1 0 27 25 2 0 27
6 0 0 11 11 0 0 11
35 3 1 107 98 7 2 107
ularis muscosa; T1b (sm), furthest invasion into submucosa.
rdiovascular Surgery c Volume 147, Number 2 767
FIGURE 1. Prevalence of metastatic pathologic nodes based on pathologic tumor depth.
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patients were thought to have EUS-staged nodes suspicious
of metastatic disease (cN1), yet all were node negative after
evaluation of the esophagectomy specimens. Figure 2 com-
pares the prevalence of predicted lymph node involvement
on EUS (cN) and positive final pathologic examination (pN)
in tumors based on their clinical tumor depth staging (cT).
There was no statistically significant difference between the
groups, but 7 patients who were thought to have T1a tumors
by EUS had positive lymph node involvement.
The sensitivity, specificity, PPV, NPV, and accuracy of
EUS for lymph node involvement (cN) were calculated.
EUS sensitivity for lymph node involvement (cN1) was
0% with a PPV of 0% because none of the patients withFIGURE 2. Prevalence of metastatic lymph nodes in EUS early-stage cT
Endoscopic ultrasound.
768 The Journal of Thoracic and Cardiovascular SurgEUS predicted to have lymph node involvement
actually had pathologically positive lymph nodes.
Conversely, the high specificity of 90% for EUS node
involvement is likely due to the large number of patients
(89/107) with pN0.
Perioperative Characteristics
A total of 105 of the 107 patients underwent a transhiatal
esophagectomy (THE), and the remaining 2 patients had a
3-hole esophagectomy. The median intraoperative blood
loss was 250 mL (range, 50-1400 mL). A single patient
required splenectomy at the time of esophagectomy
because of intraoperative splenic injury. Seven patients
received blood transfusion during their hospitalization.0-cT1 esophageal tumors: EUS cN versus esophagectomy pN. EUS,
ery c February 2014
TABLE 3. Perioperative outcomes in patients undergoing
esophagectomy for early-stage cT0-cT1 esophageal tumors
Hospital or 30-d mortality, n (%) 1 (0.9%)
Blood loss, mL, median (range) 250 (50-1400)
Perioperative blood transfusion, patients, n (%) 7 (6.5%)
Hospital length of stay, d, median (range) 8 (7-48)
Need for readmission, patients, n (%) 7 (6.5%)
Days from discharge to readmission, median (range) 3 (0-16)
Readmission length of stay, d, median (range) 4 (2-12)
Need for reoperation, n (%) 4 (3.7%)
Total complications, patients, n (%) 35 (32.7%)
Complications (most common)
Anastomotic leak 12 (11.2%)
Atrial fibrillation 12 (11.2%)
Bergeron et al General Thoracic SurgeryThe median inpatient hospital stay was 8 days (range, 7-48
days). Table 3 summarizes the esophagectomy
perioperative outcomes. There were no airway injuries or
gastrointestinal obstructions. The 30-day postoperative
mortality rate was less than 1% (1/107). The single death
occurred in a patient who had an unexplained respiratory
arrest on postoperative day 2 and for whom the family
withdrew care. He died on postoperative day 4, and
an autopsy was denied.G
T
SDISCUSSION
Carcinoma in situ (Tis) of the esophagus and early-stage
esophageal cancers are currently undergoing alternative
treatment algorithms at many institutions in place of
esophagectomy.8-10 EUS has had a major role in the
treatment planning of esophageal cancers, even for these
alternative treatments. Endoluminal treatments currently
consist primarily of EMR, RFA, and PDT. Incomplete
endoluminal resection or ablation may occur in patients
with tumor depth more advanced than demonstrated by
EUS, and these patients would have had a complete
resection and better staging with an esophagectomy. We
analyzed the results of esophagectomy specimens for
biopsy-proven Tis-T1 esophageal cancers on the basis of
on their preoperative EUS staging. Our data show that
esophagectomy is safe and effective in early-stage
esophageal cancers with a mortality rate less than 1%.
EMR produces a tissue specimen that allows for potential
accurate pathologic staging of superficial lesions, but does
not allow for accurate lymph node staging. Previous studies
have shown EMR can be definitive treatment for superficial
lesions extending to the muscularis mucosa.2 Large lesions
can be removed piecemeal; however, there is an increased
risk of metachronous neoplasia if a complete resection is not
achieved.11The risk ofmetachronous neoplasia can be limited
with robust surveillance endoscopy and biopsy.9 The second
popular alternative treatments to esophagectomy are based
on destruction of the abnormal mucosa, allowing for regener-
ationwith squamous epithelium. PDTand RFA have grown inThe Journal of Thoracic and Capopularity for the treatment of Tis and RFA for even intramu-
cosal cancer if combined with EMR.9 Drawbacks for these
methods are that there is no resulting pathologic specimen
and lymph node status is not directly addressed.
EUS is an important component for clinical staging of the
full spectrum of esophageal cancer. For Tis-T1 stage
esophageal cancers, EUS is relied on for the staging of
lymph nodes and traditionally for the depth of tumor
invasion. If by EUS the lymph nodes appear to be free of
metastatic disease, and tumor invasion is superficial, some
have advocated for endoluminal therapy of the esophageal
lesions.12 However, our data show that 9 patients (8.4%)
thought to be cN0 on EUS had pN1 on final pathology. If
these patients were to undergo endoluminal therapy, they
would have residual metastatic lymph node disease left
behind and would not have received multimodal treatment
with chemoradiotherapy until the disease had progressed.
On final pathologic staging, 8 of the 9 patients who had
lymph node metastases did have tumor penetration into or
through the submucosa (Figure 1), because none of the 48
patients with pT1a-lp tumors had lymph node involvement,
and only 1 patient with pT1a-mm had positive lymph nodes.
In the T1b-sm group, 17% had lymph node metastases.
This is consistent with other reports that submucosal tumors
have 7.5% to 45% pathologically positive nodes with
increasing tumor depth.2,13,14 Of greatest concern is that
the majority (69.2%) of our clinically staged T1a-lp tumors
were understaged by T depth, and 15% had lymph node
metastases (Figure 2). This group would have been
undertreated on the basis of EUS staging. All patients
studied had EUS performed with 7.5 and 12 MHz probes.
These probes are those that are used routinely by
referring gastroenterologists. Higher-frequency 20 and
30 MHz probes were not systematically used or evaluated.
These specific probes are not typically used for nodal
staging, but their routine incorporation into the EUS
armamentarium may improve tumor depth clinical staging.
This study investigates all types of early-stage
esophageal cancers (ie, adenocarcinoma and squamous
cell carcinoma) in all locations of the esophagus.
Those malignancies located in the cardia were excluded.
Squamous cell carcinoma is included because EUS is
used in its clinical staging.
It has been argued that patients with superficial tumors
who undergo EMR and have specimens showing a positive
deep margin or submucosal involvement should be referred
for esophagectomy, ensuring a more thorough lymph node
resection. EMR may thus have a diagnostic role for
superficial esophageal cancers.11 Long-term follow-up
data of EMR intramucosal and superficial submucosal
lesions have shown a 61% overall 5-year survival and no
tumor-related deaths.10 These data are difficult to interpret,
because many of those lesions had invasion only to the first
one third of the submucosal layer (superficial submucosa),rdiovascular Surgery c Volume 147, Number 2 769
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to determine on EMR specimens. Also, the depth of
mucosectomy associated with EMR varies. Our gastroen-
terologists use both the injection-snare and banding tech-
niques when performing EMR. Regardless of the
technique, our esophageal pathologists continue to see a
varied depth of mucosectomy in EMR specimens. This
may be due to the variation in volume of saline injected
submucosally to raise the tissue and, subsequently, how
much of the injection remains local to the desired resection
site. In addition, in BE there is a duplicated lamina propria
and muscularis mucosa,15 and more tissue superficial to the
submucosa than in the normal squamous lined esophagus.
This has been shown to affect the EUS staging accuracy
of superficial EACs16 and may hinder the performance of
EMR. One may be more likely to resect submucosa with
normal squamous mucosa than when EMR is performed
for BE. EMR may be a useful diagnostic tool but also has
some limitations in use as definitive therapy.
RFA and PDTare other endoluminal therapies that are be-
ing used in an attempt to eradicate Tis and even some
superficial EACs. However, unlike EMR, these modalities
do not produce a tissue specimen for pathologic evaluation.
Again, if EUS were used to qualify the use of RFA in the pa-
tients with early-stage esophageal cancer studied, 9 of the 90
patients thought to have cN0 would have persistent disease
in involved lymph nodes. Also, tumor depth and its correla-
tion with lymph node metastases would not be known
because of the tissue ablative nature of the technology.
Despite the recent successes of EMR and RFA in
abolishing luminal esophageal tissue, these therapies do
not address nodal spread. Patients with Tis-T1 tumors
have been shown to have a 24% rate of pathologic lymph
node spread after esophagectomy, despite being staged by
EUS to be N0.17 The cited study did not specify the depth
of T1 tumor invasion or address the limitations of EUS
for clinical decision-making, as our study did. It has also
been reported that tumors confined to the mucosa have
pathologically positive nodes 0%18 to 6.9% of the time.19
This finding is consistent with our data of 9% (1/11) of
pT1-mm tumor prevalence having pathologically positive
lymph nodes. A number of studies have reported rates of
7.5% to 50% of patients with submucosal invasion and
pathologically positive lymph nodes.13,20,21 However, in
all of our T1a tumors (T1a-lp and Ta-mm), the positive
lymph node prevalence was only 1.7% (1/59). This
difference is a result of no lymph nodes being positive in
T1a-lp tumors. Again, our data reveal a 17% rate (6/36)
of pathologically positive lymph nodes in pT1b-sm
tumors, consistent with these studies. Thus, preoperatively
predicting those patients with pT1a (pT1a-lp or
pT1a-mm) tumors without resection is difficult.
Positron emission tomography (PET) is commonly used
in the staging of esophageal malignancy. Our institution770 The Journal of Thoracic and Cardiovascular Surgdoes not have a standard algorithm mandating the
incorporation of PET in the staging of early-stage
esophageal cancers, especially in tumors thought to be
cTis. As a result, PET staging was not investigated in this
study because of the lack of its uniform use in this subgroup
of early-stage esophageal cancers.
The accuracy of EUS identifying metastatic disease in
lymph nodes has been studied. Rampado and colleagues22
reviewed 55 patients with superficial carcinoma (T1a or
T1b) and determined that NPV for EUS with nodal
involvement was 84% and diagnostic accuracy of 71%.
These results are similar to the presented data that revealed
nodal EUSNPVof 82.7% and accuracy of 75.7%. Our study
population did include a larger number of distal esophageal
tumors (90.7%vs 64%) andEACs (83.1% vs 60%) than the
referenced study. Others have reported the accuracy of EUS
in detecting malignant adenopathy to vary from 50% to
70%.23,24 Also, the type of EUS probe can affect the
accuracy, with mini-EUS probes being shown to be less ac-
curate for determining N-staging.22 The sensitivity and
specificity of EUS for determining endoscopic therapy
versus esophagectomy are poor for early-stage esophageal
cancers. Others have demonstrated that standard EUS is
not sufficient to distinguish mucosal from submucosal
invading lesions.25,26 EUS routinely understaged lesions
thought to be cT0-cT1a. Of the 46 tumors thought to be
cT1aN0 on the basis of EUS, 5 (11%) were shown to have
at least pN1 disease. EUS is insufficient for determining
lymph node involvement in early-stage esophageal cancers
not treated with esophagectomy.
Fine-needle aspiration was performed in a minority of
our patients (n¼ 11), and all were found to be cytologically
negative for inclusion in this study. Our endosonographers
are not aggressive with regard to lymph node biopsy
because of the likelihood that these patients will have a
THE for their early-stage esophageal cancer. Thus, there
may be some bias with regard to nodal EUS staging. Any
patient with fine-needle aspiration–proven pN1 disease
would have received neoadjuvant chemotherapy and
radiotherapy preoperatively and was not included in this
analysis.
Esophagectomy is a safe option in a high-volume
center, particularly for early-stage esophageal cancers.
The overall hospital mortality for this series was less than
1%. This is in agreement with other high-volume centers
where esophagectomy performed for Tis or intramucosal
adenocarcinoma has been achieved with 0% mortality.9,19
The median interval of 59 days from the date of the EUS
examination to the date of esophagectomy is attributable
to our institutional protocol of preoperative pulmonary and
physical rehabilitation before elective major surgery. The
shortcoming of esophagectomy is the rate of overall
perioperative complications, 33% in the presented series.
In a recent study by Zehetner and colleagues,9 at anotherery c February 2014
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Shigh-volume esophageal surgery center, the rate of overall
esophagectomy morbidity was 39%. More specifically, the
perioperative morbidities associated with esophagectomy
in our patients in this report, including anastomotic leak,
recurrent laryngeal nerve injury manifested by transient
hoarseness, wound infection, and chylothorax, were similar
to our institution’s previous report in 2007 on 2000 THEs.27
Despite a significant morbidity rate, our patients have had a
high long-term satisfaction rate after esophagectomy,28 a
further endorsement for esophagectomy as the optimal
choice for treatment even for early-stage cancers.
CONCLUSIONS
Endoluminal interventions, particularly EMR, will
continue to play an important and likely increasing role in
the diagnostic management of early-stage esophageal
cancers. RFA, because of its inability to produce a
diagnostic tissue specimen for pathologic review, has a
limited role in early-stage esophageal cancer management.
None of the current endoscopic-based therapies allow for
evaluation of lymph nodes. EUS has shown to be inadequate
for the definitive evaluation of lymph nodes in early-stage
esophageal cancers, and in our experience has been poor
at giving a reliable tumor depth assessment in this group.
As a result, EUS should have a limited role beyond the
initial staging examination to rule out more advanced
lesions that would require neoadjuvant therapy before
surgery. EMR may be a better staging tool for early-stage
esophageal malignancies, whether used as an adjunct to
EUS or in place of EUS. EMR is a promising staging
tool, although it is not used routinely for staging at our
institution. Esophagectomy is still the standard therapy
for early-stage esophageal cancers in the majority of
patients because it allows definitive staging of tumor depth
and nodal involvement.
The authors thank Kay Perigo for management of the University
of Michigan Esophagectomy Database.
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Dr Steven DeMeester (Los Angeles, Calif). The authors
reviewed their database from July 2005 to 2011 for clinically
staged patients, carcinoma in situ or T1, and had biopsies showing
high-grade dysplasia or invasive cancer. All the patients had EUS,
and thosewith EUS, clinical stage T2 or greater, biopsy-proven N1
disease, and neoadjuvant therapy were excluded. The final resec-
tion pathology was then used to assess the accuracy of EUS for
T and N staging.
My first question is why did the authors choose to go at it
seemingly backward? In other words, why not start with all
pathologically staged high-grade dysplasia or T1 cancers and go
back and analyze how these patients were clinically staged? Given
the shown and known inaccuracy of EUS for both Tand N staging,
howmany of the incorrectly staged T patients, such as those staged
T2 clinically and were therefore excluded from your analysis,
might have actually been T1a lesions that you should have
included, and, likewise, by excluding known N1 disease, how
many of those patients might have had a submucosal tumor and
were therefore excluded, thereby altering the true prevalence of
your nodal disease in this patient group?
Dr Bergeron. We chose to select first for the clinical staging
based on EUS because this is the typical decision-making process
that occurs for patients who are to undergo endoluminal therapies.
That is what led to our study design.
Dr DeMeester. It might be worth looking backward at it
again and just see if you come up with different numbers because
that is an important issue with the mis-staging that you have
demonstrated.
It has been well demonstrated that even with high-frequency 20
MHz ultrasound probes, differentiation between lamina propria
and muscularis mucosa invasion is difficult. I would suggest that
it is simply not possible with standard 7.5 and 12 MHz probes.
What was the impetus to try to distinguish between those with
12.5 or 7.5 MHz probes, the standard probes? Who was doing
the re-reviews? Was this you or your gastroenterology colleagues
or a combination of them?
Dr Bergeron. It was a combination as far as the review. The 20
MHz probes, some claim to be able to differentiate lamina propria
from muscularis mucosa invasion. However, surprisingly, in
the majority of the EUS reports, which included only the 7.5 or
12 MHz probes, the gastroenterologists performing the EUS
did differentiate that the tumor was invading the lamina propria
versus the muscularis mucosa. This information was routinely
included.
Dr DeMeester. I would suggest that as someonewho does them
himself, that’s simply not possible. Did you re-review the final
pathology as well? Oftentimes pathologists, particularly a number
of years ago before endoscopic resection became an important part
of the staging system, weren’t differentiating between T1a and
T1b because at that time it was all T1 lesions for them. Did you
go back and look at the pathology or had they already done a
good job of determining the precise depth of invasion on your final
pathology?
Dr Bergeron. In all of our pathologic analysis, T1a was
differentiated from T1b in the original final pathology reports.
Dr DeMeester. You demonstrated that there was only 1 patient
with an intramucosal tumor who had lymph node positivity. He772 The Journal of Thoracic and Cardiovascular Surghad invasion into the muscularis mucosa layer. But you had a small
number of patients, only 11, with invasion into the muscularis
mucosa. Larger series, such as ours, in which we had in excess
of 50 patients with invasion to the muscularis mucosa level
demonstrated only 1 patient. In other words, if you just look at
the mucosal layer alone, only 1.7% of your patients had a positive
lymph node, which compares favorably to other series. Are you
factoring that in, or are you choosing to select muscularis
mucosal invasion as a marker against endoscopic therapy, sort of
in contrast to what is accepted by most other centers for
endoscopic therapy?
Dr Bergeron. Yes, that is correct. In our experience, we had
only 1 tumor that invaded the muscularis mucosa that did have
positive nodes, and if you look at a lot of the endoscopic or
endoluminal-based therapy studies, there is a low percentage
rate of positive nodes with mucosal invasion. However, in a
previously reported study looking at minimally invasive
esophagectomy specimens, they had an approximate 6% rate of
positive lymph nodes with invasion into the muscularis mucosa.
The take-away from our review is that simply not just mucosal
invasion would be an indication for endoluminal therapy, but
potentially the more superficial lesion with only involvement of
the lamina propria might be more acceptable.
Dr DeMeester. Just one quick comment. I know your final
slide said that esophagectomy should still be considered the stan-
dard of care. I suggest that unless we as surgeons embrace
endoscopic therapy and take it on and incorporate it into our
practices, I fear for our specialty’s long-term involvement in
the esophagus.
Dr Robert Cerfolio (Birmingham, Ala). Our experience has
been similar, and I want to echo Steve’s point about us needing
to be involved. I have 2 quick questions. One, did you stratify
your data based on the endosonographer, that is, you versus the
gastroenterologist?
Dr Bergeron. All of the endosonography that was performed
was performed by gastroenterologists in this study.
Dr Cerfolio. I thought you said you were doing it when Steve
asked you.
Dr Bergeron. No. We reviewed the EUS studies, but thoracic
surgeons were not the physicians performing the endosonography.
Dr Cerfolio. So you mean you were just looking at the
ultrasound after they would do it?
Dr Bergeron.Yes. Or we were able to take the level of sublevel
of lesion penetration depth directly from the report as described by
the endosonographer.
DrCerfolio.That’s not theway to do it. I mean if you’re going to
do it, be the endosonographer and get involved. It would be inter-
esting to see if surgeons do it differently. Certainly with endobron-
chial ultrasound, I don’t think there are data yet, but I think it’s
coming that we’re going to be a little bit better at it, and I wonder
if that applies to EUS. I would like to see data on that.
You didn’t show me what you did with the patient who
has T1N1, unsuspected N1. Are you giving him adjuvant
chemotherapy when you present him at their tumor conference?
We have had incredibly heated debates. I know I don’t know
what to do. Maybe you can tell me what to tell this patient who I
have to call later today about unsuspected N1 disease; 41 nodes
were taken out, and he had 2 N1 nodes positive. He did not getery c February 2014
Bergeron et al General Thoracic Surgeryneoadjuvant therapy. Do you treat him, and if you treat him, what
do you treat him with? He’s a healthy guy, can tolerate anything,
doing great, and Eastern Cooperative Oncology Group status is
zero.
Dr Bergeron. I don’t know the answer to that. In general,
I would suspect that a patient with nodal disease would receive
adjuvant therapy at our institution if age were not prohibitive.The Journal of Thoracic and CaDr Cerfolio. You don’t know if they were treated?
Dr Bergeron. I don’t.
Dr Cerfolio. Anybody in the audience want to educate me as to
what they’re doing? (Inaudible voices from the audience.)
Dr Cerfolio. Mark Krasna said postoperative radiation and
chemotherapy. Dr DeMeester said less than 3 nodes, don’t do
anything. Interesting.rdiovascular Surgery c Volume 147, Number 2 773
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